Filing Flows › Bristol Myers Squibb (BMY) › R&D spending
Bristol Myers Squibb (BMY) R&D spending by quarter
Bristol Myers Squibb's R&D spending was $2.4B in Q3 2026 (third quarter 2026), -20% from Q2 2026. Over the last 7 quarters it ranged from $2.3B (Q1 2025) to $3.0B (Q2 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $2.4B | -20% | -6% |
| Q2 2026 | $3.0B | +12% | +15% |
| Q1 2026 | $2.6B | +2% | +17% |
| Q4 2025 | $2.6B | +2% | — |
| Q3 2025 | $2.5B | -2% | — |
| Q2 2025 | $2.6B | +14% | — |
| Q1 2025 | $2.3B | — | — |
Q3 2026 at a glance
Bristol Myers Squibb, Q3 2026: revenue $13.1B (+7% year over year), operating margin 19.4%, net earnings $2.2B, operating cash flow $4.2B. The chart follows the revenue to costs, profit and cash.
Questions
What is Bristol Myers Squibb's R&D spending?
Bristol Myers Squibb's R&D spending was $2.4B in Q3 2026 (third quarter 2026), -20% from Q2 2026.
How has Bristol Myers Squibb's R&D spending changed?
Over the last 7 quarters it ranged from $2.3B (Q1 2025) to $3.0B (Q2 2026).